Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADV7103 dose-ranging study in cystinuria
2017-002067-18Phase 2Terminated
- Sponsor
- Advicenne
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sibnayal in cystinuria (CSNU) (4 arms), sponsored by Advicenne. Primary endpoint: Percentage of urinary pH values greater than or equal to 7.0 during 24 hours on Day 7. Started Feb 2018; status: terminated.
02
Drugs
Sibnayal
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on 2017-002067-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002067-18.